Cargando…

New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist

Detalles Bibliográficos
Autor principal:	Koshak, Emad A.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2010
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883200/ https://www.ncbi.nlm.nih.gov/pubmed/20582170 http://dx.doi.org/10.4103/1817-1737.62468

Ejemplares similares

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Classification of asthma according to revised 2006 GINA: Evolution from severity to control
por: Koshak, Emad A.
Publicado: (2007)

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016)

Medication Cost-Savings and Utilization of Generic Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA) Drug Products in the USA
por: Wang, Zhong, et al.
Publicado: (2022)

Medicinal benefits of Nigella sativa in bronchial asthma: A literature review
por: Koshak, Abdulrahman, et al.
Publicado: (2017)

Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?
por: Oh, Yeon-Mok
Publicado: (2017)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
por: Beasley, Richard, et al.
Publicado: (2019)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1
por: Janeva, Elena Jovanovska, et al.
Publicado: (2015)

Skin Test Reactivity to Indoor Allergens Correlates with Asthma Severity in Jeddah, Saudi Arabia
por: Koshak, Emad A
Publicado: (2006)

Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma
por: Fingleton, James, et al.
Publicado: (2017)

The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
por: Anand, Kanika, et al.
Publicado: (2017)

Use of ICS/LABA on Asthma Exacerbation Risk in Patients Within a Medical Group
por: Stanford, Richard H., et al.
Publicado: (2015)

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
por: Lee, Su Yeon, et al.
Publicado: (2021)

THE IMPACT OF SOME DEMOGRAPHIC FACTORS ON THE SEVERITY OF ASTHMA IN CHILDREN
por: Kamfar, Hayat Z., et al.
Publicado: (2002)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?
por: Beeh, Kai M.
Publicado: (2018)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes
por: Zhang, Shiyuan, et al.
Publicado: (2023)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
por: Rogliani, Paola, et al.
Publicado: (2022)

The Effects of the FDA Warning on the Use of Droperidol by U.S. Emergency Physicians
por: Richards, John R., et al.
Publicado: (2003)

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing
por: Yim, Seon-Hee, et al.
Publicado: (2014)

Age as Maestro or Solo Instrument in Opera of Death
por: Zirpe, Kapil G, et al.
Publicado: (2021)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Oxidative Stress in Diabetic Patients with Sickle-Cell Anemia: A Warning Call for Endemic Areas
por: Mahajan, Rajiv
Publicado: (2018)

Editorial: Patient safety revisited
Publicado: (2011)

Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma
por: Caswell-Smith, Rachel, et al.
Publicado: (2017)

Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
por: Plaza, Vicente, et al.
Publicado: (2023)

Comparative Immunomodulatory Activity of Nigella sativa L. Preparations on Proinflammatory Mediators: A Focus on Asthma
por: Koshak, Abdulrahman E., et al.
Publicado: (2018)

‘Loob’ and ‘labas’: Spatial constructions of safety and risk amid the COVID-19 pandemic in the Philippines
por: Lasco, Gideon, et al.
Publicado: (2023)

Asthma guidelines: Global to local
por: FitzGerald, J. Mark
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_r9stv0m097h14948ih9jnotd4e